Edition:
India

Clearside Biomedical Inc (CLSD.OQ)

CLSD.OQ on NASDAQ Stock Exchange Global Market

10.36USD
22 Jun 2018
Change (% chg)

$0.04 (+0.39%)
Prev Close
$10.32
Open
$10.32
Day's High
$10.36
Day's Low
$10.10
Volume
714,837
Avg. Vol
236,939
52-wk High
$15.27
52-wk Low
$5.32

Latest Key Developments (Source: Significant Developments)

Clearside Biomedical Announces Positive Topline Results From Phase 2 Clinical Trial Of CLS-TA
Thursday, 31 May 2018 

May 31 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE BIOMEDICAL ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 CLINICAL TRIAL OF CLS-TA USED WITH EYLEA IN PATIENTS WITH DIABETIC MACULAR EDEMA.CLEARSIDE BIOMEDICAL INC - PRIMARY AND SECONDARY ENDPOINTS MET IN 6-MONTH TRIAL.CLEARSIDE BIOMEDICAL INC - PATIENTS TREATED WITH CLS-TA ACHIEVED COMPARABLE VISION IMPROVEMENT WITH FEWER TREATMENTS.CLEARSIDE BIOMEDICAL INC - SUPRACHOROIDAL CLS-TA USED TOGETHER WITH INTRAVITREAL EYLEA WAS GENERALLY WELL TOLERATED.  Full Article

Clearside Biomedical Q3 loss per share $0.72
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Clearside Biomedical Inc ::Clearside Biomedical, Inc. Announces third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.72.Q3 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.  Full Article

Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA
Wednesday, 25 Oct 2017 

Oct 24 (Reuters) - Clearside Biomedical Inc :Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA used together with Eylea in patients with diabetic macular edema.Clearside Biomedical Inc - ‍patient follow-up in Tybee trial is 6 months​.  Full Article

Clearside Biomedical says entered amended and restated loan and security agreement
Wednesday, 5 Oct 2016 

Clearside Biomedical Inc : On september 28, 2016, entered into an amended and restated loan and security agreement . Of $8 million term loan drawn on sept 28, about $5.3 million used to repay existing principal, interest obligations under original loan agreement. .Amended, restated loan agreement provides up to $15.0 million in new term loans of which $8 million was funded on sept 28-sec filing.  Full Article

Clearside Biomedical Q2 loss per share $0.62
Thursday, 11 Aug 2016 

Clearside Biomedical Inc : Q2 loss per share $0.62 . Clearside biomedical, inc. Reports second quarter 2016 financial results .Q2 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S.  Full Article

Clearside Biomedical provides update on phase 2 TANZANITE trial
Tuesday, 26 Jul 2016 

Clearside Biomedical Inc : 78 percent of patients required no additional treatment in trial arm with Concomitant Suprachoroidally Administered Zuprata™ and Intravitreally Administered Eylea . Patients reached an average BCVA improvement of 19 letters over a 3-month period . Expects to have an end-of-phase 2 meeting with U.S. Food and Drug Administration (FDA) in second half of 2016 .Upon FDA feedback,intends to commence phase 3 clinical program for treatment of macular edema associated with RVO in H1 of 2017.  Full Article

Wellington Management Group LLP reports 10.65 pct passicve stake in Clearside Biomedical
Monday, 11 Jul 2016 

: Wellington Management Group LLP reports 10.65 pct passicve stake in Clearside Biomedical as of June 30, 2016 - SEC Filing Source - http://bit.ly/29t07xm Further company coverage: [CLSD.O] (Bengaluru Newsroom; +1 646 223 8780).  Full Article

BRIEF-Clearside Biomedical Q1 Loss Per Share $0.62

* CLEARSIDE BIOMEDICAL ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE